Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials

Author(s): Beatrice Frigerio, José P. Werba, Mauro Amato, Alessio Ravani, Daniela Sansaro, Daniela Coggi, Lorenzo Vigo, Elena Tremoli and Damiano Baldassarre*

Volume 26, Issue 1, 2020

Page: [11 - 24] Pages: 14

DOI: 10.2174/1381612825666191213120339

Price: $65

Abstract

In the present review, associations between traditional vascular risk factors (VRFs) and carotid intimamedial thickness progression (C-IMTp) as well as the effects of therapies for VRFs control on C-IMTp were appraised to infer causality between each VRF and C-IMTp. Cohort studies indicate that smoking, binge drinking, fatness, diabetes, hypertension and hypercholesterolemia are associated with accelerated C-IMTp. An exception is physical activity, with mixed data. Interventions for the control of obesity, diabetes, hypertension and hypercholesterolemia decelerate C-IMTp. Conversely, scarce information is available regarding the effect of smoking cessation, stop of excessive alcohol intake and management of the metabolic syndrome. Altogether, these data support a causative role of several traditional VRFs on C-IMTp. Shortcomings in study design and/or ultrasonographic protocols may account for most negative studies, which underlines the importance of careful consideration of methodological aspects in investigations using C-IMTp as the outcome.

Keywords: Atherosclerosis, risk factors, carotid intima-medial thickness, atherosclerosis progression, ultrasonography, hypercholesterolemia.

« Previous Next »
[1]
Salonen R, Salonen JT. Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis 1990; 81(1): 33-40.
[http://dx.doi.org/10.1016/0021-9150(90)90056-O] [PMID: 2407252]
[2]
Schmidt-Trucksäss A, Grathwohl D, Schmid A, et al. Structural, functional, and hemodynamic changes of the common carotid artery with age in male subjects. Arterioscler Thromb Vasc Biol 1999; 19(4): 1091-7.
[http://dx.doi.org/10.1161/01.ATV.19.4.1091] [PMID: 10195940]
[3]
Yamasaki Y, Kodama M, Nishizawa H, et al. Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care 2000; 23(9): 1310-5.
[http://dx.doi.org/10.2337/diacare.23.9.1310] [PMID: 10977024]
[4]
van der Meer IM, Iglesias del Sol A, Hak AE, Bots ML, Hofman A, Witteman JC. Risk factors for progression of atherosclerosis measured at multiple sites in the arterial tree: the Rotterdam study. Stroke 2003; 34(10): 2374-9.
[http://dx.doi.org/10.1161/01.STR.0000088643.07108.19] [PMID: 12947155]
[5]
Watanabe K, Ouchi M, Ohara M, et al. Change of carotid intima-media thickness is associated with age in elderly Japanese patients without a history of cardiovascular disease. Geriatr Gerontol Int 2015; 15(8): 1023-30.
[http://dx.doi.org/10.1111/ggi.12402] [PMID: 25312290]
[6]
Lin HF, Huang LC, Chen CH, Hsu CY, Lin RT, Juo SH. Age and sex differences in the effect of parental stroke on the progression of carotid intima-media thickness. Atherosclerosis 2015; 241(1): 229-33.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.02.025] [PMID: 25724809]
[7]
Rosvall M, Persson M, Östling G, et al. Risk factors for the progression of carotid intima-media thickness over a 16-year follow-up period: the malmö diet and cancer study. Atherosclerosis 2015; 239(2): 615-21.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.01.030] [PMID: 25746169]
[8]
Huang LC, Lin RT, Chen CF, Chen CH, Juo SH, Lin HF. Predictors of carotid intima-media thickness and plaque progression in a Chinese population. J Atheroscler Thromb 2016; 23(8): 940-9.
[http://dx.doi.org/10.5551/jat.32177] [PMID: 26887219]
[9]
Ahuja V, Masaki K, Barinas-Mitchell EJ, et al. Significantly greater progression of intima-media thickness of the carotid artery in japanese american men than in white men: the ERA JUMP study. Can J Cardiol 2016; 32(10): 1246. e7- 12
[10]
Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993; 87(3)(Suppl.): II56-65.
[PMID: 8443925]
[11]
Howard G, Wagenknecht LE, Burke GL, et al. Cigarette smoking and progression of atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. JAMA 1998; 279(2): 119-24.
[http://dx.doi.org/10.1001/jama.279.2.119] [PMID: 9440661]
[12]
Kohashi K, Nakagomi A, Morisawa T, et al. Effect of smoking status on monocyte tissue factor activity, carotid atherosclerosis and long-term prognosis in metabolic syndrome. Circ J 2018; 82(5): 1418-27.
[http://dx.doi.org/10.1253/circj.CJ-17-0644] [PMID: 29225295]
[13]
Nguyen QM, Toprak A, Xu JH, Srinivasan SR, Chen W, Berenson GS. Progression of segment-specific carotid artery intima-media thickness in young adults (from the bogalusa heart study). Am J Cardiol 2011; 107(1): 114-9.
[http://dx.doi.org/10.1016/j.amjcard.2010.08.054] [PMID: 21146698]
[14]
Wagenknecht LE, Zaccaro D, Espeland MA, Karter AJ, O’Leary DH, Haffner SM. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 2003; 23(6): 1035-41.
[http://dx.doi.org/10.1161/01.ATV.0000072273.67342.6D] [PMID: 12702517]
[15]
Espeland MA, Evans GW, Wagenknecht LE, et al. Site-specific progression of carotid artery intimal-medial thickness. Atherosclerosis 2003; 171(1): 137-43.
[http://dx.doi.org/10.1016/j.atherosclerosis.2003.07.009] [PMID: 14642416]
[16]
Mackinnon AD, Jerrard-Dunne P, Sitzer M, Buehler A, von Kegler S, Markus HS. Rates and determinants of site-specific progression of carotid artery intima-media thickness: the carotid atherosclerosis progression study. Stroke 2004; 35(9): 2150-4.
[http://dx.doi.org/10.1161/01.STR.0000136720.21095.f3] [PMID: 15243147]
[17]
Chambless LE, Folsom AR, Davis V, et al. Risk factors for progression of common carotid atherosclerosis: the atherosclerosis risk in communities study, 1987-1998. Am J Epidemiol 2002; 155(1): 38-47.
[http://dx.doi.org/10.1093/aje/155.1.38] [PMID: 11772783]
[18]
Sanada S, Nishida M, Ishii K, Moriyama T, Komuro I, Yamauchi-Takihara K. Smoking promotes subclinical atherosclerosis in apparently healthy men: 2-year ultrasonographic follow-up. Circ J 2012; 76(12): 2884-91.
[http://dx.doi.org/10.1253/circj.CJ-11-1506] [PMID: 22971947]
[19]
Johnson HM, Douglas PS, Srinivasan SR, et al. Predictors of carotid intima-media thickness progression in young adults: the bogalusa heart study. Stroke 2007; 38(3): 900-5.
[http://dx.doi.org/10.1161/01.STR.0000258003.31194.0a] [PMID: 17272779]
[20]
Salonen R, Nyyssönen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92(7): 1758-64.
[http://dx.doi.org/10.1161/01.CIR.92.7.1758] [PMID: 7671358]
[21]
Polak JF, Backlund JY, Cleary PA, et al. DCCT/EDIC research group. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes 2011; 60(2): 607-13.
[http://dx.doi.org/10.2337/db10-0296] [PMID: 21270271]
[22]
Crouse JR III, Tang R, Espeland MA, Terry JG, Morgan T, Mercuri M. Associations of extracranial carotid atherosclerosis progression with coronary status and risk factors in patients with and without coronary artery disease. Circulation 2002; 106(16): 2061-6.
[http://dx.doi.org/10.1161/01.CIR.0000033833.54884.34] [PMID: 12379574]
[23]
Leone A, Giannini D, Bellotto C, Balbarini A. Passive smoking and coronary heart disease. Curr Vasc Pharmacol 2004; 2(2): 175-82.
[http://dx.doi.org/10.2174/1570161043476366] [PMID: 15320518]
[24]
Johnson HM, Piper ME, Baker TB, Fiore MC, Stein JH. Effects of smoking and cessation on subclinical arterial disease: a substudy of a randomized controlled trial. PLoS One 2012; 7(4) e35332
[http://dx.doi.org/10.1371/journal.pone.0035332] [PMID: 22496918]
[25]
Kauhanen J, Kaplan GA, Goldberg DE, Salonen R, Salonen JT. Pattern of alcohol drinking and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1999; 19(12): 3001-6.
[http://dx.doi.org/10.1161/01.ATV.19.12.3001] [PMID: 10591681]
[26]
Rantakömi SH, Laukkanen JA, Kurl S, Kauhanen J. Binge drinking and the progression of atherosclerosis in middle-aged men: an 11-year follow-up. Atherosclerosis 2009; 205(1): 266-71.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.11.004] [PMID: 19108835]
[27]
Liese AD, Nichols M, Hodo D, et al. Food intake patterns associated with carotid artery atherosclerosis in the insulin resistance atherosclerosis study. Br J Nutr 2010; 103(10): 1471-9.
[http://dx.doi.org/10.1017/S0007114509993369] [PMID: 20092665]
[28]
Mellen PB, Liese AD, Tooze JA, Vitolins MZ, Wagenknecht LE, Herrington DM. Whole-grain intake and carotid artery atherosclerosis in a multiethnic cohort: the insulin resistance atherosclerosis study. Am J Clin Nutr 2007; 85(6): 1495-502.
[http://dx.doi.org/10.1093/ajcn/85.6.1495] [PMID: 17556684]
[29]
Wu H, Dwyer KM, Fan Z, Shircore A, Fan J, Dwyer JH. Dietary fiber and progression of atherosclerosis: the Los Angeles atherosclerosis study. Am J Clin Nutr 2003; 78(6): 1085-91.
[http://dx.doi.org/10.1093/ajcn/78.6.1085] [PMID: 14668268]
[30]
Dwyer JH, Navab M, Dwyer KM, et al. Oxygenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study. Circulation 2001; 103(24): 2922-7.
[http://dx.doi.org/10.1161/01.CIR.103.24.2922] [PMID: 11413081]
[31]
Dwyer JH, Paul-Labrador MJ, Fan J, Shircore AM, Merz CN, Dwyer KM. Progression of carotid intima-media thickness and plasma antioxidants: the Los Angeles atherosclerosis study. Arterioscler Thromb Vasc Biol 2004; 24(2): 313-9.
[http://dx.doi.org/10.1161/01.ATV.0000109955.80818.8a] [PMID: 14656738]
[32]
Karppi J, Kurl S, Ronkainen K, Kauhanen J, Laukkanen JA. Serum carotenoids reduce progression of early atherosclerosis in the carotid artery wall among Eastern Finnish men. PLoS One 2013; 8(5) e64107
[http://dx.doi.org/10.1371/journal.pone.0064107] [PMID: 23700460]
[33]
Jung S, Kim MK, Shin J, et al. High sodium intake and sodium to potassium ratio may be linked to subsequent increase in vascular damage in adults aged 40 years and older: the Korean multi-rural communities cohort (MRCohort). Eur J Nutr 2019; 58(4): 1659-71.
[http://dx.doi.org/10.1007/s00394-018-1712-3] [PMID: 29761317]
[34]
Ellingsen I, Seljeflot I, Arnesen H, Tonstad S. Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: A 3-year intervention study. Nutr Metab Cardiovasc Dis 2009; 19(1): 8-14.
[http://dx.doi.org/10.1016/j.numecd.2008.01.006] [PMID: 18472409]
[35]
Murie-Fernandez M, Irimia P, Toledo E, et al. PREDIMED Investigators. Carotid intima-media thickness changes with Mediterranean diet: a randomized trial (PREDIMED-Navarra). Atherosclerosis 2011; 219(1): 158-62.
[http://dx.doi.org/10.1016/j.atherosclerosis.2011.06.050] [PMID: 21802081]
[36]
Sala-Vila A, Romero-Mamani ES, Gilabert R, et al. Changes in ultrasound-assessed carotid intima-media thickness and plaque with a Mediterranean diet: a substudy of the PREDIMED trial. Arterioscler Thromb Vasc Biol 2014; 34(2): 439-45.
[http://dx.doi.org/10.1161/ATVBAHA.113.302327] [PMID: 24285581]
[37]
Petersen KS, Clifton PM, Blanch N, Keogh JB. Effect of improving dietary quality on carotid intima media thickness in subjects with type 1 and type 2 diabetes: a 12-mo randomized controlled trial. Am J Clin Nutr 2015; 102(4): 771-9.
[http://dx.doi.org/10.3945/ajcn.115.112151] [PMID: 26354542]
[38]
Mita T, Watada H, Ogihara T, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis 2007; 191(1): 162-7.
[http://dx.doi.org/10.1016/j.atherosclerosis.2006.03.005] [PMID: 16616147]
[39]
Colussi G, Catena C, Dialti V, Mos L, Sechi LA. Effects of the consumption of fish meals on the carotid IntimaMedia thickness in patients with hypertension: a prospective study. J Atheroscler Thromb 2014; 21(9): 941-56.
[http://dx.doi.org/10.5551/jat.22921] [PMID: 24727682]
[40]
Hodis HN, Mack WJ, Kono N, et al. Women’s Isoflavone soy health research group. Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial. Stroke 2011; 42(11): 3168-75.
[http://dx.doi.org/10.1161/STROKEAHA.111.620831] [PMID: 21903957]
[41]
Azen SP, Qian D, Mack WJ, et al. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation 1996; 94(10): 2369-72.
[http://dx.doi.org/10.1161/01.CIR.94.10.2369] [PMID: 8921775]
[42]
Magliano D, McNeil J, Branley P, et al. The Melbourne Atherosclerosis Vitamin E Trial (MAVET): a study of high dose vitamin E in smokers. Eur J Cardiovasc Prev Rehabil 2006; 13(3): 341-7.
[http://dx.doi.org/10.1097/00149831-200606000-00008] [PMID: 16926662]
[43]
Hodis HN, Mack WJ, LaBree L, et al. VEAPS research group. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 2002; 106(12): 1453-9.
[http://dx.doi.org/10.1161/01.CIR.0000029092.99946.08] [PMID: 12234947]
[44]
Lonn E, Yusuf S, Dzavik V, et al. SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103(7): 919-25.
[http://dx.doi.org/10.1161/01.CIR.103.7.919] [PMID: 11181464]
[45]
Salonen JT, Nyyssönen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000; 248(5): 377-86.
[http://dx.doi.org/10.1046/j.1365-2796.2000.00752.x] [PMID: 11123502]
[46]
Salonen RM, Nyyssönen K, Kaikkonen J, et al. Antioxidant supplementation in atherosclerosis prevention study. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003; 107(7): 947-53.
[http://dx.doi.org/10.1161/01.CIR.0000050626.25057.51] [PMID: 12600905]
[47]
Nordstrom CK, Dwyer KM, Merz CN, Shircore A, Dwyer JH. Leisure time physical activity and early atherosclerosis: the Los Angeles atherosclerosis study. Am J Med 2003; 115(1): 19-25.
[http://dx.doi.org/10.1016/S0002-9343(03)00242-0] [PMID: 12867230]
[48]
Krause N, Brand RJ, Kaplan GA, et al. Occupational physical activity, energy expenditure and 11-year progression of carotid atherosclerosis. Scand J Work Environ Health 2007; 33(6): 405-24.
[http://dx.doi.org/10.5271/sjweh.1171] [PMID: 18327509]
[49]
Kozàkovà M, Palombo C, Morizzo C, Nolan JJ, Konrad T, Balkau B. RISC investigators. Effect of sedentary behaviour and vigorous physical activity on segment-specific carotid wall thickness and its progression in a healthy population. Eur Heart J 2010; 31(12): 1511-9.
[http://dx.doi.org/10.1093/eurheartj/ehq092] [PMID: 20400760]
[50]
Magalhães JP, Melo X, Correia IR, et al. Effects of combined training with different intensities on vascular health in patients with type 2 diabetes: a 1-year randomized controlled trial. Cardiovasc Diabetol 2019; 18(1): 34.
[http://dx.doi.org/10.1186/s12933-019-0840-2] [PMID: 30885194]
[51]
Cayres SU, de Lira FS, Kemper HCG, Codogno JS, Barbosa MF, Fernandes RA. Sport-based physical activity recommendations and modifications in C-reactive protein and arterial thickness. Eur J Pediatr 2018; 177(4): 551-8.
[http://dx.doi.org/10.1007/s00431-018-3101-6] [PMID: 29374832]
[52]
Wildman RP, Schott LL, Brockwell S, Kuller LH, Sutton-Tyrrell K. A dietary and exercise intervention slows menopause-associated progression of subclinical atherosclerosis as measured by intima-media thickness of the carotid arteries. J Am Coll Cardiol 2004; 44(3): 579-85.
[http://dx.doi.org/10.1016/j.jacc.2004.03.078] [PMID: 15358024]
[53]
Okada K, Maeda N, Tatsukawa M, Shimizu C, Sawayama Y, Hayashi J. The influence of lifestyle modification on carotid artery intima-media thickness in a suburban Japanese population. Atherosclerosis 2004; 173(2): 329-37.
[http://dx.doi.org/10.1016/j.atherosclerosis.2003.12.025] [PMID: 15064110]
[54]
Sanches PL, de Piano A, Campos RM, et al. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy. J Clin Lipidol 2014; 8(3): 265-72.
[http://dx.doi.org/10.1016/j.jacl.2014.02.007] [PMID: 24793347]
[55]
Masquio DC, de Piano A, Sanches PL, et al. The effect of weight loss magnitude on pro-/anti-inflammatory adipokines and carotid intima-media thickness in obese adolescents engaged in interdisciplinary weight loss therapy. Clin Endocrinol (Oxf) 2013; 79(1): 55-64.
[http://dx.doi.org/10.1111/j.1365-2265.2012.04504.x] [PMID: 22809141]
[56]
Kuller LH, Pettee Gabriel KK, Kinzel LS, et al. The Women on the Move Through Activity and Nutrition (WOMAN) study: final 48-month results. Obesity (Silver Spring) 2012; 20(3): 636-43.
[http://dx.doi.org/10.1038/oby.2011.80] [PMID: 21494228]
[57]
Anderssen SA, Hjelstuen AK, Hjermann I, Bjerkan K, Holme I. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis 2005; 178(2): 387-97.
[http://dx.doi.org/10.1016/j.atherosclerosis.2004.08.033] [PMID: 15694949]
[58]
Stevens J. Juhaeri, Cai J, Evans GW. Impact of body mass index on changes in common carotid artery wall thickness. Obes Res 2002; 10(10): 1000-7.
[http://dx.doi.org/10.1038/oby.2002.136] [PMID: 12376580]
[59]
Reed D, Dwyer KM, Dwyer JH. Abdominal obesity and carotid artery wall thickness. The Los Angeles atherosclerosis study. Int J Obes Relat Metab Disord 2003; 27(12): 1546-51.
[http://dx.doi.org/10.1038/sj.ijo.0802468] [PMID: 14634688]
[60]
Koskinen J, Kähönen M, Viikari JS, et al. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults: the cardiovascular risk in young Finns study. Circulation 2009; 120(3): 229-36.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.845065] [PMID: 19581494]
[61]
Lakka TA, Lakka HM, Salonen R, Kaplan GA, Salonen JT. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis 2001; 154(2): 497-504.
[http://dx.doi.org/10.1016/S0021-9150(00)00514-1] [PMID: 11166785]
[62]
Buscemi S, Batsis JA, Verga S, et al. Long-term effects of a multidisciplinary treatment of uncomplicated obesity on carotid intima-media thickness. Obesity (Silver Spring) 2011; 19(6): 1187-92.
[http://dx.doi.org/10.1038/oby.2010.313] [PMID: 21183931]
[63]
Woo KS, Chook P, Yu CW, et al. Effects of diet and exercise on obesity-related vascular dysfunction in children. Circulation 2004; 109(16): 1981-6.
[http://dx.doi.org/10.1161/01.CIR.0000126599.47470.BE] [PMID: 15066949]
[64]
Pacifico L, Arca M, Anania C, Cantisani V, Di Martino M, Chiesa C. Arterial function and structure after a 1-year lifestyle intervention in children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2013; 23(10): 1010-6.
[http://dx.doi.org/10.1016/j.numecd.2012.08.003] [PMID: 23018041]
[65]
Karason K, Wikstrand J, Sjöström L, Wendelhag I. Weight loss and progression of early atherosclerosis in the carotid artery: a four-year controlled study of obese subjects. Int J Obes Relat Metab Disord 1999; 23(9): 948-56.
[http://dx.doi.org/10.1038/sj.ijo.0801024] [PMID: 10490801]
[66]
Gómez-Martin JM, Aracil E, Galindo J, Escobar-Morreale HF, Balsa JA, Botella-Carretero JI. Improvement in cardiovascular risk in women after bariatric surgery as measured by carotid intima-media thickness: comparison of sleeve gastrectomy versus gastric bypass. Surg Obes Relat Dis 2017; 13(5): 848-54.
[http://dx.doi.org/10.1016/j.soard.2017.01.040] [PMID: 28411021]
[67]
Jonker FHW, van Houten VAA, Wijngaarden LH, et al. Age-related effects of bariatric surgery on early atherosclerosis and cardiovascular risk reduction. Obes Surg 2018; 28(4): 1040-6.
[http://dx.doi.org/10.1007/s11695-017-2962-5] [PMID: 29043547]
[68]
O’Leary DH, Reuwer AQ, Nissen SE, et al. AUDITOR investigators. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart 2011; 97(14): 1143-50.
[http://dx.doi.org/10.1136/hrt.2011.223446] [PMID: 21610270]
[69]
Matoba Y, Inoguchi T, Suzuki S, et al. Impact of metabolic syndrome on the progression of intima-media thickening in Japanese-a follow-up study. Diabetes Res Clin Pract 2009; 86(3): e50-3.
[http://dx.doi.org/10.1016/j.diabres.2009.09.013] [PMID: 19818522]
[70]
Wallenfeldt K, Hulthe J, Fagerberg B. The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow-up. J Intern Med 2005; 258(1): 28-37.
[http://dx.doi.org/10.1111/j.1365-2796.2005.01511.x] [PMID: 15953130]
[71]
Jung JM, Young Kwon D, Han C, Park MH. Metabolic syndrome and early carotid atherosclerosis in the elderly. J Atheroscler Thromb 2014; 21(5): 435-44.
[http://dx.doi.org/10.5551/jat.18655] [PMID: 24477027]
[72]
Ferreira I, Beijers HJ, Schouten F, Smulders YM, Twisk JW, Stehouwer CD. Clustering of metabolic syndrome traits is associated with maladaptive carotid remodeling and stiffening: a 6-year longitudinal study. Hypertension 2012; 60(2): 542-9.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.194738] [PMID: 22733470]
[73]
Herder M, Arntzen KA, Johnsen SH, Mathiesen EB. The metabolic syndrome and progression of carotid atherosclerosis over 13 years. The Tromsø study. Cardiovasc Diabetol 2012; 11: 77.
[http://dx.doi.org/10.1186/1475-2840-11-77] [PMID: 22738646]
[74]
Zanchetti A, Hennig M, Baurecht H, et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens 2007; 25(12): 2463-70.
[http://dx.doi.org/10.1097/HJH.0b013e3282f063d5] [PMID: 17984668]
[75]
Fan AZ. Metabolic syndrome and progression of atherosclerosis among middle-aged US adults. J Atheroscler Thromb 2006; 13(1): 46-54.
[http://dx.doi.org/10.5551/jat.13.46] [PMID: 16505591]
[76]
Koskinen J, Magnussen CG, Taittonen L, et al. Arterial structure and function after recovery from the metabolic syndrome: the cardiovascular risk in young Finns study. Circulation 2010; 121(3): 392-400.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.894584] [PMID: 20065161]
[77]
Femia R, Kozakova M, Nannipieri M, et al. Carotid intima-media thickness in confirmed prehypertensive subjects: predictors and progression. Arterioscler Thromb Vasc Biol 2007; 27(10): 2244-9.
[http://dx.doi.org/10.1161/ATVBAHA.107.149641] [PMID: 17656672]
[78]
Sander D, Schulze-Horn C, Bickel H, Gnahn H, Bartels E, Conrad B. Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. Stroke 2006; 37(2): 351-7.
[http://dx.doi.org/10.1161/01.STR.0000199034.26345.bc] [PMID: 16373634]
[79]
Gómez-Marcos MA, Recio-Rodríguez JI, Gómez-Sánchez L, et al. LOD-DIABETES Group. Gender differences in the progression of target organ damage in patients with increased insulin resistance: the LOD-DIABETES study. Cardiovasc Diabetol 2015; 14: 132.
[http://dx.doi.org/10.1186/s12933-015-0293-1] [PMID: 26427534]
[80]
Zhao B, Liu Y, Zhang Y, et al. Gender difference in carotid intima-media thickness in type 2 diabetic patients: a 4-year follow-up study. Cardiovasc Diabetol 2012; 11: 51.
[http://dx.doi.org/10.1186/1475-2840-11-51] [PMID: 22583598]
[81]
van den Berg E, Biessels GJ, Stehouwer CD, et al. Ten-year time course of risk factors for increased carotid intima-media thickness: the hoorn study. Eur J Cardiovasc Prev Rehabil 2010; 17(2): 168-74.
[http://dx.doi.org/10.1097/HJR.0b013e3283319094] [PMID: 19940777]
[82]
Kim HJ, Ahn CW, Kang ES, et al. The level of 2-h post-challenge glucose is an independent risk factor of carotid intima-media thickness progression in Korean type 2 diabetic patients. J Diabetes Complications 2007; 21(1): 7-12.
[http://dx.doi.org/10.1016/j.jdiacomp.2005.11.004] [PMID: 17189868]
[83]
Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. Serum glycated albumin predicts the progression of carotid arterial atherosclerosis. Atherosclerosis 2012; 225(2): 450-5.
[http://dx.doi.org/10.1016/j.atherosclerosis.2012.09.005] [PMID: 23040867]
[84]
Mete M, Wilson C, Lee ET, et al. Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience. J Diabetes Complications 2011; 25(6): 362-7.
[http://dx.doi.org/10.1016/j.jdiacomp.2011.04.001] [PMID: 21775166]
[85]
Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35(5): 1073-8.
[http://dx.doi.org/10.1161/01.STR.0000125864.01546.f2] [PMID: 15073402]
[86]
Yamasaki Y, Katakami N, Hayaishi-Okano R, et al. alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract 2005; 67(3): 204-10.
[http://dx.doi.org/10.1016/j.diabres.2004.07.012] [PMID: 15713352]
[87]
Mita T, Watada H, Shimizu T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 2007; 27(11): 2456-62.
[http://dx.doi.org/10.1161/ATVBAHA.107.152835] [PMID: 17872451]
[88]
Mita T, Katakami N, Yoshii H, et al. Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016; 39(1): 139-48.
[http://dx.doi.org/10.2337/dc15-0781] [PMID: 26628419]
[89]
Mita T, Katakami N, Shiraiwa T, et al. Collaborators on the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) Trial. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): a randomized controlled trial. Diabetes Care 2016; 39(3): 455-64.
[http://dx.doi.org/10.2337/dc15-2145] [PMID: 26822324]
[90]
Katakami N, Yamasaki Y, Hayaishi-Okano R, et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia 2004; 47(11): 1906-13.
[http://dx.doi.org/10.1007/s00125-004-1547-8] [PMID: 15565373]
[91]
Esposito K, Giugliano D, Nappo F, Marfella R. Campanian postprandial hyperglycemia study group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110(2): 214-9.
[http://dx.doi.org/10.1161/01.CIR.0000134501.57864.66] [PMID: 15197140]
[92]
Hodis HN, Mack WJ, Zheng L, et al. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. Diabetes Care 2006; 29(7): 1545-53.
[http://dx.doi.org/10.2337/dc05-2462] [PMID: 16801577]
[93]
Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the rosiglitazone atherosclerosis study. J Intern Med 2007; 261(3): 293-305.
[http://dx.doi.org/10.1111/j.1365-2796.2007.01767.x] [PMID: 17305652]
[94]
Yee MS, Pavitt DV, Dhanjil S, Godsland IF, Richmond W, Johnston DG. The effects of rosiglitazone on atherosclerotic progression in patients with type 2 diabetes at high cardiovascular risk. Diabet Med 2010; 27(12): 1392-400.
[http://dx.doi.org/10.1111/j.1464-5491.2010.03089.x] [PMID: 21059092]
[95]
Lonn EM, Gerstein HC, Sheridan P, et al. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) and STARR Investigators. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (Study of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol 2009; 53(22): 2028-35.
[http://dx.doi.org/10.1016/j.jacc.2008.12.072] [PMID: 19477351]
[96]
Saremi A, Schwenke DC, Buchanan TA, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33(2): 393-9.
[http://dx.doi.org/10.1161/ATVBAHA.112.300346] [PMID: 23175674]
[97]
Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296(21): 2572-81.
[http://dx.doi.org/10.1001/jama.296.21.joc60158] [PMID: 17101640]
[98]
Yamasaki Y, Katakami N, Furukado S, et al. Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. J Atheroscler Thromb 2010; 17(11): 1132-40.
[http://dx.doi.org/10.5551/jat.4663] [PMID: 20686324]
[99]
Xiang AH, Peters RK, Kjos SL, et al. Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. J Clin Endocrinol Metab 2005; 90(4): 1986-91.
[http://dx.doi.org/10.1210/jc.2004-1685] [PMID: 15623809]
[100]
Xiang AH, Hodis HN, Kawakubo M, et al. Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis 2008; 199(1): 207-14.
[http://dx.doi.org/10.1016/j.atherosclerosis.2007.10.016] [PMID: 18054942]
[101]
Lonn EM, Bosch J, Diaz R, et al. GRACE and ORIGIN Investigators. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care 2013; 36(9): 2466-74.
[http://dx.doi.org/10.2337/dc12-2129] [PMID: 23564916]
[102]
Nathan DM, Lachin J, Cleary P, et al. Diabetes control and complications trial; epidemiology of diabetes interventions and complications research group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348(23): 2294-303.
[http://dx.doi.org/10.1056/NEJMoa022314] [PMID: 12788993]
[103]
Kendrick J, Chonchol M, Gnahn H, Sander D. Higher systolic blood pressure is associated with progression of carotid intima-media thickness in patients with chronic kidney disease. Kidney Int 2010; 77(9): 794-800.
[http://dx.doi.org/10.1038/ki.2009.557] [PMID: 20130527]
[104]
Zheng L, Hodis HN, Buchanan TA, Li Y, Mack WJ. Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Am J Cardiol 2007; 99(7): 956-60.
[http://dx.doi.org/10.1016/j.amjcard.2006.10.061] [PMID: 17398191]
[105]
Salonen JT, Seppänen K, Lakka TA, Salonen R, Kaplan GA. Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis 2000; 148(2): 265-73.
[http://dx.doi.org/10.1016/S0021-9150(99)00272-5] [PMID: 10657561]
[106]
Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008; 118(24): 2515-22.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.772665] [PMID: 19029469]
[107]
Zureik M, Touboul PJ, Bonithon-Kopp C, et al. Cross-sectional and 4-year longitudinal associations between brachial pulse pressure and common carotid intima-media thickness in a general population. The EVA study. Stroke 1999; 30(3): 550-5.
[http://dx.doi.org/10.1161/01.STR.30.3.550] [PMID: 10066851]
[108]
Lakka TA, Salonen R, Kaplan GA, Salonen JT. Blood pressure and the progression of carotid atherosclerosis in middle-aged men. Hypertension 1999; 34(1): 51-6.
[http://dx.doi.org/10.1161/01.HYP.34.1.51] [PMID: 10406823]
[109]
Rizzoni D, Muiesan ML, Salvetti M, et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens 2001; 19(4): 703-11.
[http://dx.doi.org/10.1097/00004872-200104000-00007] [PMID: 11330873]
[110]
Rossi R, Nuzzo A, Olaru AI, Origliani G, Modena MG. Endothelial function affects early carotid atherosclerosis progression in hypertensive postmenopausal women. J Hypertens 2011; 29(6): 1136-44.
[http://dx.doi.org/10.1097/HJH.0b013e328345d950] [PMID: 21505359]
[111]
Tattersall MC, Gassett A, Korcarz CE, et al. Predictors of carotid thickness and plaque progression during a decade: the multi-ethnic study of atherosclerosis. Stroke 2014; 45(11): 3257-62.
[http://dx.doi.org/10.1161/STROKEAHA.114.005669] [PMID: 25213342]
[112]
D’Amato A, Mancusi C, Losi MA, et al. Target organ damage and target systolic blood pressure in clinical practice: the campania salute network. Am J Hypertens 2018; 31(6): 658-64.
[http://dx.doi.org/10.1093/ajh/hpy007] [PMID: 29566163]
[113]
Zanchetti A, Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16(11): 1667-76.
[http://dx.doi.org/10.1097/00004872-199816110-00014] [PMID: 9856368]
[114]
Zanchetti A, Bond MG, Hennig M, et al. European lacidipine study on atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106(19): 2422-7.
[http://dx.doi.org/10.1161/01.CIR.0000039288.86470.DD] [PMID: 12417537]
[115]
Zanchetti A, Bond MG, Hennig M, et al. ELSA Investigators. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2004; 22(6): 1201-12.
[http://dx.doi.org/10.1097/00004872-200406000-00022] [PMID: 15167456]
[116]
Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. MORE study investigators. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007; 1(2): 97-106.
[http://dx.doi.org/10.1177/1753944707085982] [PMID: 19124398]
[117]
Nezu T, Hosomi N, Aoki S, et al. Effects of cilnidipine, an L/N-type calcium channel blocker, on carotid atherosclerosis in Japanese post-stroke hypertensive patients: results from the CA-ATTEND Study. J Atheroscler Thromb 2018; 25(6): 490-504.
[http://dx.doi.org/10.5551/jat.42101] [PMID: 29225324]
[118]
Stanton AV, Chapman JN, Mayet J, et al. Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Clin Sci (Lond) 2001; 101(5): 455-64.
[http://dx.doi.org/10.1042/cs1010455] [PMID: 11672450]
[119]
Hosomi N, Mizushige K, Ohyama H, et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001; 32(7): 1539-45.
[http://dx.doi.org/10.1161/01.STR.32.7.1539] [PMID: 11441198]
[120]
Simon A, Gariépy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103(24): 2949-54.
[http://dx.doi.org/10.1161/01.CIR.103.24.2949] [PMID: 11413085]
[121]
Hoogerbrugge N, de Groot E, de Heide LH, et al. Doxazosin atherosclerosis progression study in hypertensives in the Netherlands. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Neth J Med 2002; 60(9): 354-61.
[PMID: 12572707]
[122]
MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 collaborative research group. Prevention of atherosclerosis with ramipril. J Am Coll Cardiol 2000; 36(2): 438-43.
[http://dx.doi.org/10.1016/S0735-1097(00)00736-1] [PMID: 10933355]
[123]
Asselbergs FW, van Roon AM, Hillege HL, et al. PREVEND IT Investigators. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke 2005; 36(3): 649-53.
[http://dx.doi.org/10.1161/01.STR.0000155731.92786.e9] [PMID: 15692120]
[124]
Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008; 299(14): 1678-89.
[http://dx.doi.org/10.1001/jama.299.14.1678] [PMID: 18398080]
[125]
Herder M, Johnsen SH, Arntzen KA, Mathiesen EB. Risk factors for progression of carotid intima-media thickness and total plaque area: a 13-year follow-up study: the Tromsø Study. Stroke 2012; 43(7): 1818-23.
[http://dx.doi.org/10.1161/STROKEAHA.111.646596] [PMID: 22550052]
[126]
Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004; 35(10): 2248-52.
[http://dx.doi.org/10.1161/01.STR.0000140629.65145.3c] [PMID: 15345795]
[127]
Fujii K, Abe I, Ohya Y, et al. Risk factors for the progression of early carotid atherosclerosis in a male working population. Hypertens Res 2003; 26(6): 465-71.
[http://dx.doi.org/10.1291/hypres.26.465] [PMID: 12862203]
[128]
Salonen JT, Salonen R, Seppänen K, Kantola M, Suntioinen S, Korpela H. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. BMJ 1991; 302(6779): 756-60.
[http://dx.doi.org/10.1136/bmj.302.6779.756] [PMID: 2021765]
[129]
Larsson H, Berglund G, Ahrén B. Insulin sensitivity, insulin secretion, and glucose tolerance versus intima-media thickness in nondiabetic postmenopausal women. J Clin Endocrinol Metab 2003; 88(10): 4791-7.
[http://dx.doi.org/10.1210/jc.2003-030329] [PMID: 14557456]
[130]
Karim R, Mack WJ, Lobo RA, et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: estrogen in the prevention of atherosclerosis. Trial Menopause 2005; 12(4): 366-73.
[131]
Kozakova M, Palombo C, Morizzo C, et al. Obesity and carotid artery remodeling. Nutr Diabetes 2015; 5 e177
[http://dx.doi.org/10.1038/nutd.2015.26] [PMID: 26302064]
[132]
Maki KC, Davidson MH, Dicklin MR, Bell M, Witchger M, Feinstein SB. Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. J Clin Lipidol 2011; 5(3): 141-51.
[http://dx.doi.org/10.1016/j.jacl.2011.02.003] [PMID: 21600518]
[133]
Fan AZ, Dwyer JH. Sex differences in the relation of HDL cholesterol to progression of carotid intima-media thickness: the Los Angeles atherosclerosis study. Atherosclerosis 2007; 195(1): e191-6.
[http://dx.doi.org/10.1016/j.atherosclerosis.2007.03.045] [PMID: 17482196]
[134]
Shin S, Lee SH, Park S, et al. Soluble fms-like tyrosine kinase-1 and the progression of carotid intima-media thickness - 24-month follow-up study -. Circ J 2010; 74(10): 2211-5.
[http://dx.doi.org/10.1253/circj.CJ-10-0432] [PMID: 20689217]
[135]
Maki KC, Dicklin MR, Davidson MH, Mize PD, Kulkarni KR. Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women. Vasc Health Risk Manag 2012; 8: 31-8.
[http://dx.doi.org/10.2147/VHRM.S27963] [PMID: 22272073]
[136]
Schmidt C, Wikstrand J. High apoB/apoA-I ratio is associated with increased progression rate of carotid artery intima-media thickness in clinically healthy 58-year-old men: experiences from very long-term follow-up in the AIR study. Atherosclerosis 2009; 205(1): 284-9.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.11.025] [PMID: 19124125]
[137]
Boras J, Ljubic S, Car N, et al. Lipoprotein(a) predicts progression of carotid artery intima-media thickening in patients with type 2 diabetes: a four-year follow-up. Wien Klin Wochenschr 2010; 122(5-6): 159-64.
[http://dx.doi.org/10.1007/s00508-010-1318-0] [PMID: 20361379]
[138]
van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart 2003; 89(8): 893-6.
[http://dx.doi.org/10.1136/heart.89.8.893] [PMID: 12860867]
[139]
Herder M, Arntzen KA, Johnsen SH, Eggen AE, Mathiesen EB. Long-term use of lipid-lowering drugs slows progression of carotid atherosclerosis: the Tromso study 1994 to 2008. Arterioscler Thromb Vasc Biol 2013; 33(4): 858-62.
[http://dx.doi.org/10.1161/ATVBAHA.112.300767] [PMID: 23393396]
[140]
Furberg CD, Adams HP Jr, Applegate WB, et al. Asymptomatic Carotid Artery Progression Study (ACAPS) research group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90(4): 1679-87.
[http://dx.doi.org/10.1161/01.CIR.90.4.1679] [PMID: 7734010]
[141]
Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD. Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. Am J Cardiol 1995; 76(9): C47-53.
[http://dx.doi.org/10.1016/S0002-9149(99)80470-6] [PMID: 7572686]
[142]
Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996; 124(6): 548-56.
[http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00002] [PMID: 8597317]
[143]
Byington RP, Evans GW, Espeland MA, et al. Asymptomatic Carotid Artery Progression Study (ACAPS) research group. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Circulation 1999; 100(3): e14-7.
[http://dx.doi.org/10.1161/01.CIR.100.3.e14] [PMID: 10411862]
[144]
Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75(7): 455-9.
[http://dx.doi.org/10.1016/S0002-9149(99)80580-3] [PMID: 7863988]
[145]
Salonen R, Nyssönen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995; 76(9): C34-9.
[http://dx.doi.org/10.1016/S0002-9149(99)80468-8] [PMID: 7572684]
[146]
Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the carotid atherosclerosis italian ultrasound study. Am J Med 1996; 101(6): 627-34.
[http://dx.doi.org/10.1016/S0002-9343(96)00333-6] [PMID: 9003110]
[147]
Bots ML, Palmer MK, Dogan S, et al. METEOR study group. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. J Intern Med 2009; 265(6): 698-707.
[http://dx.doi.org/10.1111/j.1365-2796.2009.02073.x] [PMID: 19298496]
[148]
Crouse JR III, Bots ML, Evans GW, et al. METEOR study group. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. Eur J Cardiovasc Prev Rehabil 2010; 17(2): 223-9.
[http://dx.doi.org/10.1097/HJR.0b013e3283359c38] [PMID: 20038840]
[149]
Crouse JR III, Raichlen JS, Riley WA, et al. METEOR study group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297(12): 1344-53.
[http://dx.doi.org/10.1001/jama.297.12.1344] [PMID: 17384434]
[150]
Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106(16): 2055-60.
[http://dx.doi.org/10.1161/01.CIR.0000034508.55617.65] [PMID: 12379573]
[151]
Nakagomi A, Shibui T, Kohashi K, et al. Differential effects of atorvastatin and pitavastatin on inflammation, insulin resistance, and the carotid intima-media thickness in patients with dyslipidemia. J Atheroscler Thromb 2015; 22(11): 1158-71.
[http://dx.doi.org/10.5551/jat.29520] [PMID: 26084792]
[152]
Beishuizen ED, van de Ree MA, Jukema JW, et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2004; 27(12): 2887-92.
[http://dx.doi.org/10.2337/diacare.27.12.2887] [PMID: 15562202]
[153]
MacMahon S, Sharpe N, Gamble G, et al. LIPID trial research group. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID atherosclerosis substudy. Circulation 1998; 97(18): 1784-90.
[http://dx.doi.org/10.1161/01.CIR.97.18.1784] [PMID: 9603532]
[154]
de Groot E, Jukema JW, Montauban van Swijndregt AD, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998; 31(7): 1561-7.
[http://dx.doi.org/10.1016/S0735-1097(98)00170-3] [PMID: 9626835]
[155]
Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103(13): 1721-6.
[http://dx.doi.org/10.1161/01.CIR.103.13.1721] [PMID: 11282901]
[156]
Ikeda K, Takahashi T, Yamada H, et al. for the PEACE Investigators. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). Eur J Prev Cardiol 2013; 20(6): 1069-79.
[http://dx.doi.org/10.1177/2047487312451539] [PMID: 22689416]
[157]
Baldassarre D, Veglia F, Gobbi C, et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis 2000; 151(2): 575-83.
[http://dx.doi.org/10.1016/S0021-9150(99)00434-7] [PMID: 10924737]
[158]
Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993; 88(1): 20-8.
[http://dx.doi.org/10.1161/01.CIR.88.1.20] [PMID: 8319334]
[159]
Mack WJ, Selzer RH, Hodis HN, et al. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 1993; 24(12): 1779-83.
[http://dx.doi.org/10.1161/01.STR.24.12.1779] [PMID: 8248954]
[160]
Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008; 52(25): 2198-205.
[http://dx.doi.org/10.1016/j.jacc.2008.10.031] [PMID: 19095139]
[161]
Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361(22): 2113-22.
[http://dx.doi.org/10.1056/NEJMoa0907569] [PMID: 19915217]
[162]
Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010; 55(24): 2721-6.
[http://dx.doi.org/10.1016/j.jacc.2010.03.017] [PMID: 20399059]
[163]
Taylor AJ, Villines TC, Stanek EJ. Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe. Eur Heart J 2012; 33(23): 2939-45.
[http://dx.doi.org/10.1093/eurheartj/ehs105] [PMID: 22564353]
[164]
de Sauvage Nolting PR, de Groot E, Zwinderman AH, Buirma RJ, Trip MD, Kastelein JJ. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 2003; 163(15): 1837-41.
[http://dx.doi.org/10.1001/archinte.163.15.1837] [PMID: 12912721]
[165]
Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357(9256): 577-81.
[http://dx.doi.org/10.1016/S0140-6736(00)04053-8] [PMID: 11558482]
[166]
van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 2005; 95(2): 264-6.
[http://dx.doi.org/10.1016/j.amjcard.2004.09.015] [PMID: 15642565]
[167]
Kinouchi K, Ichihara A, Bokuda K, Morimoto S, Itoh H. Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. J Atheroscler Thromb 2013; 20(3): 245-56.
[http://dx.doi.org/10.5551/jat.14860] [PMID: 23197250]
[168]
Kastelein JJ, Akdim F, Stroes ES, et al. ENHANCE investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358(14): 1431-43.
[http://dx.doi.org/10.1056/NEJMoa0800742] [PMID: 18376000]
[169]
Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292(3): 331-7.
[http://dx.doi.org/10.1001/jama.292.3.331] [PMID: 15265847]
[170]
Kastelein JJ, van Leuven SI, Burgess L, et al. RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356(16): 1620-30.
[http://dx.doi.org/10.1056/NEJMoa071359] [PMID: 17387131]
[171]
Bots ML, Visseren FL, Evans GW, et al. RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370(9582): 153-60.
[http://dx.doi.org/10.1016/S0140-6736(07)61088-5] [PMID: 17630038]
[172]
Schwartz GG, Olsson AG, Abt M, et al. dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367(22): 2089-99.
[http://dx.doi.org/10.1056/NEJMoa1206797] [PMID: 23126252]
[173]
Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012; 14(1): 1-10.
[http://dx.doi.org/10.1007/s11883-011-0219-7] [PMID: 22102062]
[174]
Barter PJ, Caulfield M, Eriksson M, et al. ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357(21): 2109-22.
[http://dx.doi.org/10.1056/NEJMoa0706628] [PMID: 17984165]
[175]
Costanzo P, Perrone-Filardi P, Vassallo E, et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol 2010; 56(24): 2006-20.
[http://dx.doi.org/10.1016/j.jacc.2010.05.059] [PMID: 21126642]
[176]
Goldberger ZD, Valle JA, Dandekar VK, Chan PS, Ko DT, Nallamothu BK. Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis. Am Heart J 2010; 160(4): 701-14.
[http://dx.doi.org/10.1016/j.ahj.2010.06.029] [PMID: 20934565]
[177]
Bots ML, Taylor AJ, Kastelein JJ, et al. Rate of change in carotid intima-media thickness and vascular events: meta-analyses cannot solve all the issues. A point of view. J Hypertens 2012; 30(9): 1690-6.
[PMID: 22895014]
[178]
Lorenz MW, Polak JF, Kavousi M, et al. PROG-IMT study group. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379(9831): 2053-62.
[http://dx.doi.org/10.1016/S0140-6736(12)60441-3] [PMID: 22541275]
[179]
Lorenz MW, Price JF, Robertson C, et al. Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration. Diabetes Care 2015; 38(10): 1921-9.
[http://dx.doi.org/10.2337/dc14-2732] [PMID: 26180107]
[180]
Lorenz MW, Gao L, Ziegelbauer K, et al. PROG-IMT study group. Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - results from the PROG-IMT collaboration. PLoS One 2018; 13(4) e0191172
[http://dx.doi.org/10.1371/journal.pone.0191172] [PMID: 29649236]
[181]
Baldassarre D, Veglia F, Hamsten A, et al. IMPROVE study group. Progression of carotid intima-media thickness as predictor of vascular events: results from the IMPROVE study. Arterioscler Thromb Vasc Biol 2013; 33(9): 2273-9.
[http://dx.doi.org/10.1161/ATVBAHA.113.301844] [PMID: 23825364]
[182]
Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
[http://dx.doi.org/10.1177/003591576505800503] [PMID: 14283879]
[183]
Höfler M. The bradford hill considerations on causality: a counterfactual perspective. Emerg Themes Epidemiol 2005; 2: 11.
[http://dx.doi.org/10.1186/1742-7622-2-11] [PMID: 16269083]

Rights & Permissions Print Cite
Article Metrics
12
1
© 2024 Bentham Science Publishers | Privacy Policy